SPORE IN BREAST CANCER

乳腺癌中的孢子

• 批准号: 6951285
• 负责人: VIRGIL CRAIG JORDAN
• 金额: $ 25万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6951285
• 关键词: breast neoplasms

This SCORE application submitted in response to the RFA from National Cancer Institute, will take advantage of the strengths in breast cancer research and treatment that exist at the Robert H. Lurie Comprehensive Cancer Center. The SPORE will provide the infrastructure to bring together basic scientists and clinicians to rapidly test new approaches in the prevention, early detection, diagnosis and treatment of human breast cancer. The specific themes of the SPORE are: 1. To investigate the role of diet and hormones in breast carcinogenesis. 2. To study the cell and molecular biology of breast cancer. 3. To evaluate factors associated with breast cancer risk and prevention. 4. To implement innovative translational therapies for breast cancer. The SPORE application consists of six principal research projects, three career development projects, five pilot projects and four Core facilities to support the research. The principal research projects are: #1. Drug resistance to anti-estrogens (PI Jordan), #2. Actions of estrogen agonists and antagonists by non-classical transcription pathways (PI Jameson), #3, Dietary and hormonal modifications of breast carcinogenesis in transgenic mice (PI Thor), #4. Estradiol levels in breast fluid, saliva and serum samples (PI Chatterton), #5. Anti-estrogens and breast density and pre-menopausal women (PI Morrow), #6 Angiostatic therapy for breast cancer: a translational study (PI Soff). The Core facilities include: Administration,, Tissue Resources, Clinical and Biostatistical Cores. The investigators selected to be part of the SPORE Program come from a variety of disciplines ranging from Clinical Programs to Chemical Engineering, Pathology and Microbiology-Immunology. To maintain meaningful communication between investigators, we will have monthly meetings of SPORE investigators, an annual retreat, monthly meetings of the Executive Committee and each investigator will be actively involved with at least one project (or core) in addition to their own. Based on the infrastructure described, our large patient population and our track record of productivity, we believe that the Robert H. Lurie Comprehensive Cancer Center is well suited for the SPORE program.

该分数申请是针对国家癌症研究所的RFA提交的，将利用Robert H. Lurie综合癌症中心存在的乳腺癌研究和治疗中的优势。孢子将提供基础设施，使基础科学家和临床医生迅速测试人类乳腺癌的预防，早期发现，诊断和治疗的新方法。孢子的特定主题是：1。研究饮食和激素在乳腺癌发生中的作用。 2。研究乳腺癌的细胞和分子生物学。 3。评估与乳腺癌风险和预防相关的因素。 4。用于实施乳腺癌的创新转化疗法。孢子应用包括六个主要研究项目，三个职业发展项目，五个试点项目和四个支持研究的核心设施。主要研究项目是：＃1。抗雌激素的耐药性（PI Jordan），＃2。雌激素激动剂和拮抗剂通过非古典转录途径（PI Jameson），＃3，转基因小鼠（PI Thor）中乳腺癌发生的饮食和荷尔蒙修饰，＃4。乳液，唾液和血清样品（PI Chatterton）中的雌二醇水平，＃5。抗雌激素和乳房密度和绝经前妇女（PI Morrow），＃6乳腺癌血管静脉治疗：一项转化研究（PI SOFF）。核心设施包括：给药，组织资源，临床和生物统计核心。被选为孢子计划一部分的研究人员来自各种学科，从临床计划到化学工程，病理学和微生物学 - 免疫学。为了维持调查人员之间有意义的沟通，我们将每月举行孢子调查人员的会议，每年的务虚会，执行委员会的每月会议，每个调查人员除了自己之外，还将与至少一个项目（或核心）积极参与。根据所描述的基础设施，我们的大量患者人群和生产力的记录，我们认为罗伯特·H·卢里综合癌症中心非常适合孢子计划。

项目成果

Role of TGF-beta in cancer and the potential for therapy and prevention.

• DOI: 10.1586/14737140.4.4.649
• 发表时间: 2004-08-01
• 期刊: Expert review of anticancer therapy
• 影响因子: 3.3
• 作者: Kaklamani, Virginia G;Pasche, Boris
• 通讯作者: Pasche, Boris

Who should not receive chemotherapy? Data from American databases and trials.

哪些人不应该接受化疗？

• DOI: 10.1093/oxfordjournals.jncimonographs.a003446
• 发表时间: 2001
• 期刊: Journal of the National Cancer Institute. Monographs
• 作者: Morrow,M;Krontiras,H
• 通讯作者: Krontiras,H

The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma.

同侧全乳腺超声检查对乳腺癌手术治疗的影响。

• DOI: 10.1016/s0002-9610(03)00280-0
• 发表时间: 2003
• 期刊: American journal of surgery
• 影响因子: 3
• 作者: Golshan,Mehra;Fung,BingB;Wolfman,Judith;Rademaker,Alfred;Morrow,Monica
• 通讯作者: Morrow,Monica

Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.

表达野生型雌激素受体的乳腺癌细胞中雌激素受体α选择性雌激素受体调节剂复合物激活的基因表达谱。

• 发表时间: 2002
• 期刊: Cancer research.
• 作者: Levenson,AnaitS;Svoboda,KristenM;Pease,KatherineM;Kaiser,ScottA;Chen,Bin;Simons,LauraA;Jovanovic,BorkoD;Dyck,PatriciaA;Jordan,VCraig
• 通讯作者: Jordan,VCraig

Estrogen receptors as therapeutic targets in breast cancer.

• DOI: 10.1002/9783527623297.ch5
• 发表时间: 2006-01
• 期刊: Current topics in medicinal chemistry
• 影响因子: 3.4
• 作者: E. Ariazi;Jennifer L. Ariazi;Jennifer L. Ariazi;F. Cordera;V. Jordan